Татьяна Александровна Титова
Russian Cancer Research Center NN Blokhin · 40 works · 19 citations · h-index 2
Top works
- 50P Prognostic value of disseminated tumor cells (DTC) identification in bone marrow from patients with advanced gastric or esophagogastric junction (EGJ) adenocarcinoma (interim results)
- Ramucirumab in the treatment of refractory metastatic gastric cancer: Results from the RamSelGa trial
- The use of neoadjuvant hormone therapy in locally advanced luminal breast cancer
- Analysis of prognostic factors for survival in the Russian population of patients with disseminated gastric cancer, who received ramucirumab as secondline therapy in the RAMSELGA trial
- REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE
- Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia
- Case report of partial response on second line with Ramucirumab and FOLFIRI in treatment of 74 year old male with metastatic HER2-negative gastric adenocarcinoma
- Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer
- Efficacy of perioperative FOLFIRINOX chemotherapy versus FLOT chemotherapy in patients with resectable adenocarcinoma of the stomach or gastroesophageal junction (SIEWERT types II–III, cT4aN0M0, T1–4cN+ cM0): preliminary results of the study
- Clinical experience: Ramucirumab with FOLFIRI/XELIRI as a second-line for patients with metastatic gastric cancer
- A case of effective disease control of advanced gastric cancer following ramucirumab plus FOLFIRI in second line treatment in clinical practice
- 45P Alofanib in subsequent therapy of advanced gastric cancer: Final results from the phase Ib clinical trial
- Роль препаратов платины в неоадъювантной химиотерапии BRCA-ассоциированного тройного негативного рака молочной железы: предварительные результаты одноцентрового исследования
- Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer
- РАМУЦИРУМАБ В КОМБИНАЦИИ С ПАКЛИТАКСЕЛОМ ИЛИ FOLFIRI ВО ВТОРОЙ ЛИНИИ ЛЕЧЕНИЯ БОЛЬНЫХ ДИССЕМИНИРОВАННЫМ РАКОМ ЖЕЛУДКА ПОСЛЕ ДОЦЕТАКСЕЛА В ПЕРВОЙ ЛИНИИ В РУТИННОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ
- RAMUCIRUMAB IN A COMBINATION WITH IRINOTECAN-BASED TWO-COMPONENT THERAPY REGIMEN AS THE SECOND LINE FOR THE TREATMENT OF DISSEMINATED GASTRIC CANCER. CASE REPORT
- КЛИНИЧЕСКИЙ ПРИМЕР ДЛИТЕЛЬНОГО КОНТРОЛЯ ДИССЕМИНИРОВАННОГО ПЕРСТНЕВИДНОКЛЕТОЧНОГО РАКА ЖЕЛУДКА НА ФОНЕ ХИМИОТЕРАПИИ ВТОРОЙ ЛИНИИ ЛЕЧЕНИЯ В КОМБИНАЦИИ С БЕВАЦИЗУМАБОМ
- Clinical example of long-term control of disseminated signet-ring cell carcinoma of the stomach against the background of chemotherapy of the second line of treatment in combination with bevacizumab
- Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy
- Colon-patch oesophagoplasty with complication of transplant perforation in patient with local recurrent gastric cancer